$RGEN News

Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Repligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Wolfe Research Assumes Repligen at Outperform, Announces Price Target of $145

Repligen Has A Cleaner Recovery Angle, But With High Valuation

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

Q1 Rundown: Repligen (NASDAQ:RGEN) Vs Other Drug Development Inputs & Services Stocks

Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report

Why Repligen (RGEN) Stock Is Trading Up Today

3 Small-Cap Stocks We Steer Clear Of

RBC Capital Reinstates Outperform on Repligen, Announces $160 Price Target

5 Revealing Analyst Questions From Repligen’s Q1 Earnings Call

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Barclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $165

Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises

Barclays Maintains Overweight on Repligen, Raises Price Target to $160

Repligen Reshapes Operations And China Reach As Valuation Signals Upside

Repligen Q1 Earnings Call Highlights

Repligen Corporation Q1 2026 Earnings Call Summary